最新の一覧

*, Corresponding Author

Omori K, Nakamura A, Miyoshi H, Takase T, Cho KY, Ono K, Manda N, Kurihara Y, Aoki S, Atsumi T. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. Metabolism. 98:27-36, 2019

Omori K, Nomoto H, Nakamura A, Takase T, Cho KY, Ono K, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Reduction of glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: a randomized controlled trial of repaglinide vs. sulfonylurea. J Diabetes Invest. 10:367-374, 2019

Takahashi K, Cho KY, Nakamura A, Miya A, Miyoshi A, Yamamoto C, Nomoto H, Niwa H, Takahashi K, Manda N, Kurihara Y, Aoki S, Ito Y, Atsumi T, Miyoshi H. Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicentre observational study in Japanese patients with type 2 diabetes. J Diabetes Invest. 10:429-438, 2019

Shibayama Y, Kameda H, Ohta S, Cho KY, Nakamura A, Miyoshi H, Atsumi T. Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab. J Diabetes Invest. 10: 1385-1387, 2019

Nomoto H, Kameda H, Nakamura A, Tsuchida K, Yamamoto C, Nagai S, Atsumi T, Miyoshi H. Breakdown of autonomously functioning thyroid nodule accompanied by acromegaly after octreotide treatment. Frontiers in Endocrinology.10: Article 131 , 2019

Takase T, Nakamura A, Yamamoto C, Nomoto H, Miya A, Dannoura M, Cho KY, Kurihara Y, Manda N, Aoki S, Atsumi T, Miyoshi HImprovement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: a randomized controlled trial. J Diabetes Invest. 10:699-705, 2019

Yamauchi Y, Nakamura Y, Takahashi K, Takase T, Yamamoto C, Atsumi T. Miyoshi H.  Factors with remission of fatty liver in patients with type 2 diabetes treated with ipragliflozin. Endocrin J. 66; 995-1000, 2019

Sato M, Miyoshi H, Nakamura A, Sumi N, Kamoshima H, Ono Y. Cross-Cultural Adaptation of the Chronic Illness Resources Survey in Japanese Patients with Diabetes.Jpn J Nurs Sci.2019 in press

Miya A, Nakamura A, Miyoshi H, Atsumi T. Gitelman’s Syndrome with hyperphosphatemia, effectively responding to single oral magnesium oxide administration. Medicine98(28): e16408, 2019

Cho KY, Nakamura A, Omori K, Takase T, Miya A, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H⋆. Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type-2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial. Daiabetes Obes Metab. 21:710-714, 2019 

Yamamoto K, Miyoshi H, Cho KY, Nakamura A, Greenberg AS, Atsumi T. Overexpression of Perilipin1 protects against atheroma progression in apolipoprotein E knockout mice. Atherosclerosis. 269: 192-196, 2019

Nomoto H, Miyoshi H, Nakamura A, et al. Potential Importance of a Histopathological Analysis in Thyroidal Diseases with High Serum IgG4 Levels. Intern Med. 57(3):453, 2018

Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, Miyoshi H, Sakamoto N. Liver steatosis and dislipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.  PLoS One. 13: e0209615, 2018 

Takase T, Nakamura A, Miyoshi H*, et al. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. Endocrine J. 31; 64(3):363-367, 2017

Oita Y, Miyoshi H, Ono K, et al. Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes – Randomized controlled study-. Endocrine J. 65: 141-150, 2018

Yanagiya S, Cho KY, Nakamura A, Nomoto H, Kawamoto Y, Miyoshi H, Atsumi T. The effect of everolimus on refractory hypoglycemia in a patient with inoperable metastatic insulinoma evaluated by continuous glucose monitoring. Intern Med. 57: 2527-2531, 2018

Kitao N, Miyoshi H, Furumoto T, et al. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). Cardiovasc Diabetol. 16: 125, 2018

Takahashi K, Nakamura A, Miyoshi H, Nomoto H, Kitao N, Omori K, Yamamoto K, Cho KY, Terauchi Y, Atsumi T. Effect Impact  of the sodium-–glucose -cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages. Sci Rep. 8; 6864, 2018

Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Serum adiponectin and insulin secretion: a direct or inverse association? J Diabetes Invest. 9: 1106-1109, 2018

Takase T, Nakamura A, Yamamoto C, Atsumi T, Miyoshi H*. Improvement in the proinsulin/C-peptide ratio during treatment with ipragliflozin in Japanese patients with type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy. 19: 631-632, 2018